PharmaCielo Struggles To Complete Financing, Extends Closing To March
It appears that PharmaCielo (TSXV: PCLO) is having a difficult time raising funds for its operations. The firm this morning announced further delays to the final closing of a financing announced in December.
The company is currently looking to raise $15.0 million from the sale of debenture units in a non-brokered offering. The units bear interest at a rate of 11% per annum, are valid for three years, and contain 250 common share purchase warrants. Warrants are valid for a period of 36 months, and contain a maturity of 50% over the offering price at the time of the initial closing. Debt under the offering is secured by the assets of the company.
Originally estimating to sell 15,000 units at $1,000 per each, the firm expected to close the offering on December 30, with proceeds being used for operations, working capital, and the build-out of its dry flower sales program.
However, the firm managed to close just $5.0 million in gross proceeds on December 31, which included a portion of insider participation.
The remaining portion of the financing however is now not expected to close until March 4, pending ongoing discussions with certain parties.
PharmaCielo last traded at $1.07 on the TSX Venture.
Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.
